ClinicalTrials.gg
CompletedNCT02956525Updated Sep 9, 2026

Phase I Study to Evaluate the Safety of Dexibuprofen 200mg Under Fasting and Fed Conditions

A Phase 1 interventional study of Dexibuprofen in Healthy Volunteers, sponsored by Apsen Farmaceutica S.A.. Completed at 1 site in Brazil. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Apsen Farmaceutica S.A. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Phase I Study to Evaluate the Safety of Dexibuprofen 200mg (Apsen Pharmaceuticals A / S.) After a Single and Multiple Dose Oral Administration in Healthy Participants of Both Sexes Under Fasting and Fed Conditions.

Read the detailed description

A single oral dose of test medicine will be administered to participants in a practical period with the aid of 200 mL of water at room temperature. During administration, participants should stay in seated position. Participants will be confined at least 12 hours prior to administration and will remain for about 24 hours after the same, totaling about 36 hours of confinement.

After 36 hours of confinement the participantes will proceed to the multi-dose use phase for seven days in fed conditions.

To assess safety, an evaluation of the vital signs, laboratory tests and health status of the participants will be carried out throughout the study.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Apsen Farmaceutica S.A. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant able to understand and sign the of the study;
  • Healthy research participant, of both sexes, aged between 18 and 50 years, with between 18.50 and 29.99 kg / m2;
  • Participant considered healthy by evaluating the medical history, vital signs and general clinical examination;
  • The results of clinical laboratory tests (biochemistry, hematology, serology, urinalysis and certified by cardiologists) within the normal range established by the laboratory or changes that are considered not by study physician.

Exclusion criteria

Exclusion Criteria:

  • History of any major surgery in the last three months;
  • History present or previous history of any cardiac event, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric, hematologic, considered by the investigator as and can endanger the participant's health;
  • History of chronic alcohol abuse, drugs, drugs and / or smoking in the last 6 months;
  • Known to dexibuprofen, ibuprofen or its related (other nonsteroidal anti-inflammatory drugs) as well as components present in the formulation;
  • History of use of drugs that potentially interfere with the kinetics / dynamics dexibuprofen or any other medication considered clinically significant by the investigator with time less than 7 times of drug half-life preceding the period of inclusion;
  • Regular consumption of grapefruit and / or their derivatives;
  • Pregnant women and nursing mothers;
  • Donation or loss of 450 ml or more of blood within 3 months before the study and / or hospitalization for any reason, up to 4 weeks before the beginning of it.
  • Participation in any clinical trial in the last 12 months preceding the start of the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Dexibuprofen 200 mg - Fed

    Fed condition

    Drug: Dexibuprofen

  • Experimental
    Dexibuprofen 200 mg - Fasting

    Fasting condition

    Drug: Dexibuprofen

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the safety of the drug through the incidence and classification of adverse events following single and multiple dose administration.

    Adverse events both recorded in the single-dose and multiple-dose

    Time frame: 40 days

Secondary outcomes

  1. To evaluate the pharmacokinetics of the drug dexibuprofen at 200 mg concentration after single dose oral administration under fasting and fed conditions.

    Evaluation of pharmacokinetic parameters: Tmax, Cmax, AUC, DV, Kel, CL and T1/2.

    Time frame: 36 hours

07

Study locations

1 site
  • Azidus laboratories Ltd.
    Valinhos, São Paulo 13271-130, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Jul 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2016
First posted
Nov 7, 2016
StartActual
Apr 1, 2018
Primary completionActual
Jul 1, 2018
CompletionActual
Jul 1, 2018
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02956525
Lead sponsor
Apsen Farmaceutica S.A.
Responsible party
Sponsor
First posted
Nov 7, 2016
Start date
Apr 1, 2018
Primary completion
Jul 1, 2018
Completion
Jul 1, 2018
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexibuprofen

Start the discussion